Cook MyoSite, Inc. is a subsidiary of Cook Group established in 2002, specializing in muscle-derived cell therapy manufacturing and contract services. The company has over 20 years of GMP manufacturing expertise in autologous muscle-derived cell (AMDC) technologies, with its lead product iltamiocel under FDA RMAT designation for female stress urinary incontinence. Cook MyoSite also provides contract manufacturing services to partners such as Lipella Pharmaceuticals and Imagine Pharma for cell-based therapeutic products.
Muscle-derived cell therapy, autologous cell manufacturing, GMP cell manufacturing, cell isolation technology
1 site worldwide
Involvement in 2 clinical trials
No reviews available yet.
No documents available.